Get Varubi Online

Varubi (rolapitant) is a prescription antiemetic that blocks neurokinin-1 (NK1) receptors in the brain. Substance P, a neuropeptide that binds NK1 receptors, plays a key role in triggering the delayed vomiting response after chemotherapy. By blocking these receptors, rolapitant helps prevent nausea and vomiting that typically begins more than 24 hours after a chemotherapy dose.

Varubi is taken as a single oral dose approximately 1 to 2 hours before each chemotherapy cycle. It is not taken daily and does not need to be re-dosed within the same chemotherapy cycle. It is always used as part of a broader antiemetic regimen that typically includes a 5-HT3 antagonist and dexamethasone.

Delayed chemotherapy-induced nausea and vomiting (CINV) refers to nausea and vomiting that begins more than 24 hours after chemotherapy administration and can last several days. This is distinct from acute CINV, which occurs within the first 24 hours. Delayed CINV is particularly associated with highly emetogenic agents such as cisplatin and certain moderately emetogenic regimens.

Varubi should not be used in patients who are taking thalidomide, as rolapitant inhibits the CYP2D6 enzyme and can significantly increase levels of certain co-administered drugs. Patients with severe hepatic impairment require caution. Your physician will review all current medications and medical history before prescribing to ensure Varubi is appropriate and safe for you.

The most commonly reported side effects of Varubi in clinical trials include neutropenia (low white blood cell counts), hiccups, decreased appetite, and dizziness. Most side effects were consistent with effects seen in patients undergoing chemotherapy. Contact your physician if you experience unusual symptoms, particularly signs of infection or prolonged dizziness.

Yes. Varubi is designed to be used in combination with other antiemetics. The standard regimen pairs it with a 5-HT3 receptor antagonist such as ondansetron and a corticosteroid such as dexamethasone. This combination approach targets multiple pathways involved in chemotherapy-induced nausea to provide broader protection across both acute and delayed phases.

Doctronic uses an AI-powered evaluation to gather your symptoms, medical history, and relevant information before connecting you with a licensed physician. The physician reviews your case, makes a clinical determination, and if appropriate, creates a personalized treatment plan that may include a prescription. The entire process is designed to be thorough, safe, and convenient.

Yes. Doctronic connects patients with real, licensed physicians who review every case individually. All consultations are HIPAA-compliant, and prescribing decisions are made by qualified doctors, not algorithms. The platform is available to adults 18 and older in any U.S. state.